SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

New River Pharmaceuticals Inc – ‘8-K’ for 6/26/06 – EX-99.1

On:  Monday, 6/26/06, at 2:34pm ET   ·   For:  6/26/06   ·   Accession #:  1140361-6-9539   ·   File #:  0-50851

Previous ‘8-K’:  ‘8-K’ on / for 6/20/06   ·   Next:  ‘8-K’ on / for 6/30/06   ·   Latest:  ‘8-K’ on 4/24/07 for 4/18/07

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 6/26/06  New River Pharmaceuticals Inc     8-K:8,9     6/26/06    2:1.1M                                   Summit Fin’l Printing

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         New River Pharmaceutical 8-K 6-26-2006              HTML     22K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML    177K

EX-99.1   —   Miscellaneous Exhibit

This exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]

  Exhibit 99.1  
Donald R. Jasinski, M.D.
The Johns Hopkins University
Baltimore, MD
Lisdexamfetamine Dimesylate
(NRP104 / LDX)
Clinical Abuse Liability Studies
 
 
 
Forward-Looking Statements
This presentation may contain forward-looking
statements that reflect management’s current views as to
New River Pharmaceuticals Inc.’s clinical trials,
regulatory approval process, product development,
research programs and other future events and
operations. These forward-looking statements involve
uncertainties and risks that are detailed in New River
Pharmaceutical Inc.’s Annual Report on Form 10-K filed
with the SEC on March 15, 2006, as well as other public
filings with the SEC. Actual results could differ materially
from these forward-looking statements.
 
 
 
Study A01
A Single-Blind, Placebo- and Active-
Controlled, Single-Dose Escalation
Study of NRP104 (up to 150 mg) to
Evaluate Safety, Tolerability, and Abuse
Liability in Healthy Adult Volunteers
with Histories of Stimulant Abuse
 
 
 
Cohort
Placebo
d-Amphetamine, mg
NRP104, mg
1
Yes
40
30
50
70
100
 
 
2
Yes
40
 
50
70
100
130
 
3
Yes
40
 
 
70
100
130
150
Study A01
Treatment
n
3 Cohorts of 4 subjects each
–
each of 12 subjects received 4 single doses of NRP104in a dose-escalation fashion, 1 single dose of d-amphetamine, and 1 dose of placebo
n
Minimum 2-day interval between dosing
n
PK and PD measures before dosing and at 0.5, 1,  1.5, 2, 3, 4, 5, 6, 9, 12, 16 and 24 hours after dosing
 
 
 
Study A01
Subject Eligibility
n
All subjects had history of stimulant abuse
n
No other clinically significant Axis I psychiatric disordersother than substance abuse
n
Could not be currently physically dependent on
benzodiazepines (urine drug screen)
–
opiates (naloxone challenge, 0.4 mg and 1 mg)
–
–
ETOH (Breathalyzer test)
n
No concomitant medications allowed (other than femalehormonal contraceptives or HRT)
n
Minimum Grade 6 reading level as determined by theRapid Estimation of Adult Literacy in Medicine (REALM)
 
 
 
Characteristic
N = 12
Age, years
Mean ± SD
Median (range)
 
43 ± 5.9
44 (29 - 52)
Sex, n (%)
Male
 
12 (100)
Race, n (%)
White
Black
Asian
 
1 (8.3)
10 (83.3)
1 (8.3)
Height, cm
Mean ± SD
Median (range)
 
172.8 ± 6.7
174 (160 - 183)
Weight, kg
Mean ± SD
Median (range)
 
74.6 ± 10.8
72 (58 - 94)
REALM test score
Mean ± SD
Median (range)
 
61.8 ± 7.6
64.5 (43 - 66)
REALM = Rapid Estimation of Adult Literacy in Medicine.
Study A01
Demographics and Baseline
Characteristics
 
 
 
Study A01
Subject Disposition
n
12 subjects were enrolled, randomized, and received at least 1 dose
n
11 subjects completed the study
–
1 subject was withdrawn due to “reactive hypertensive” after the second dose of d-amphetamine
n
not deemed a withdrawal caused by an adverse event
 
 
 
Study A01
Cohort 1
n
Four subjects completed
n
NRP104
–
30, 50, 70, 100 mg
 
 
 
n = 4
0
10
20
30
40
50
60
70
80
90
100
110
120
130
140
150
160
0.0
4.0
8.0
12.0
16.0
20.0
24.0
NRP104 30 mg
NRP104 50 mg
NRP104 70 mg
NRP104 100 mg
d-Amphetamine sulfate 40 mg
Placebo
Study A01
PK Data: Cohort 1
Mean d-amphetamine
Concentration‑Time Plots
 
 
 
Study A01
Cohort 2
n
Four subjects completed
n
NRP104
–
50, 70, 100, 130 mg
 
 
 
Study A01
PK Data: Cohort 2
Mean d-amphetamine Concentration- Time Plots
 
 
 
Study A01
PK Data: Cohort 2
Mean d-amphetamine Concentration- Time Plots
 
 
 
Study A01
Cohort 3
n
Three of four subjects completed
n
NRP104
–
70, 100, 130, 150 mg
 
 
 
n = 3 or 4
0
10
20
30
40
50
60
70
80
90
100
110
120
130
140
150
160
0.0
4.0
8.0
12.0
16.0
20.0
24.0
NRP104 70 mg
NRP104 100 mg
NRP104 130 mg
NRP104 150 mg
d-Amphetamine sulfate 40 mg
Placebo
Study A01
PK Data: Cohort 3
Mean d-amphetamine
Concentration‑Time Plots
 
 
 
Study A01
PK Data: Cohort 3
Mean d-amphetamine
Concentration‑Time Plots
 
 
 
Study A01
A01 Summary
n
Overall, d-amphetamine produced the expected subjective, behavioral, and cardiovascular effects that were distinguished from placebo
n
Comparable doses of NRP104 tended to be less euphoric overall and more dysphoric with a later peak effect
n
PK and PD data consistent with pre-clinical studies of rate limited hydrolysis
n
Slower absorption phase
n
Doses 50, 100, and 150 mg of NRP104 are safe and suitable for crossover study
 
 
 
Study A02
A Double- Blind Placebo- and Active-
Controlled, Single-Dose Crossover
Pharmacodynamic and Pharmacokinetic
Study to Evaluate the Safety, Tolerability
and Abuse Liability of Intravenously
administered NRP104 25 mg and 50 mg
in Healthy Adult Volunteers with Histories
of Stimulant Abuse
 
 
 
Study A02
Study Design
n
Phase II, randomized, single-center, double-blind dose run-up study
n
Conducted at an in-patient residential unit
–
subjects confined to clinic for a minimum of 14 days
n
Included a screening phase and an NRP104 dose run-up phase
 
 
 
Study A02
Subject Population
n
≥ 18 and ≤ 55 years of age
n
Meet DSM-IV criteria for the diagnosis of substance abuse
n
Have a history of IV drug use
n
Not physically dependent on benzodiazepines, opiates, or alcohol
n
Minimal reading level of grade 6, determined by the Rapid Estimation of Adult Literacy in Medicine (REALM) at investigator’s discretion
n
No presence of a severe learning difficulty or mental retardation
 
 
 
Study A02
Primary Objectives
n
Investigate safety and abuse liability of a single intravenous (IV) dose of NRP104 in healthy adults with a history of stimulant abuse
n
Compare safety profile with d-amphetamine and placebo
n
Gather estimates of abuse liability
 
 
 
Cohort
Subject, n
NRP104
d-amphetamine
Placebo
1
3
25 mg
10 mg
Yes
2
9
50 mg
20 mg
Yes
Study A02
Treatment
n
Each subject received 1 single IV dose of NRP104, 1 single IV dose of d-amphetamine sulfate, and 1 placebo IV
dose
n
Minimum 2-day interval between dosing
n
3-way crossover drug administration
 
 
 
Study A02
Assessments
n
Abuse liability assessments
–
Drug Rating Questionnaire – Subject (DRQS)
–
Drug Rating Questionnaire – Observer (DRQO)
–
Treatment Enjoyment Assessment Questionnaire (TEAQ)
–
Addiction Research Center Inventory (ARCI) –  to assess the degree of amphetamine like effects with Amphetamine and Benzedrine Group
Subscales
n
Cardiovascular assessments
–
systolic and diastolic blood pressure and pulse
n
Safety assessments
–
adverse events monitored
n
Pharmacokinetic assessments
 
 
 
Study A02
Subject Disposition
n
12 Subjects were enrolled, randomized, and received at least 1 dose
n
All 12 subjects completed the study
n
There were no protocol deviations on inclusion/exclusion criteria and no subjects were withdrawn due to protocol
violations
 
 
 
Characteristic
N = 12
Age, years
Mean ± SD
Median (range)
 
45.9 ± 3.3
45.5 (42 - 52)
Sex, n (%)
Male
 
12 (100)
Race, n (%)
White
Black
 
1 (8)
11 (92)
Height, cm
Mean ± SD
Median (range)
 
176 ± 7.1
175.7 (159.5 - 185.4)
Weight, kg
Mean ± SD
Median (range)
 
69.5 ± 10.3
68.8 (53.5 - 91.2)
Study A02
Demographics and Baseline Characteristics
 
 
 
PK Data: Cohort 1
Mean d-amphetamine Concentration‑Time Plots in Semi‑Logarithmic Scales
A = 25 mg NRP104
B = 10 mg Dextroamphetamine
C = Placebo
Study A02
 
 
 
0.00
5.00
10.00
15.00
20.00
Time, hr
0.00
5.00
10.00
15.00
20.00
Time, hr
0.00
5.00
10.00
15.00
20.00
Time, hr
Do you feel a drug effect now?
Mean response
NRP104 25 mg
Placebo
d-amphetamine 10 mg
Study A02
DRQS – Feel Drug Effect: Cohort 1
 
 
 
Do you like the drug effect you are feeling now?
Mean Response
2.5
5.0
7.5
10.0
NRP104 25 mg
0.00
5.00
10.00
15.00
20.00
Time, hr
Placebo
0.00
5.00
10.00
15.00
20.00
Time, hr
d-amphetamine 10 mg
0.00
5.00
10.00
15.00
20.00
Time, hr
Study A02
DRQS – Liking: Cohort 1
 
 
 
Drug Chosen to Take Again
 
Subject
Drug
1
1
d-amphetamine 10 mg
2
3
d-amphetamine 10 mg
3
4
d-amphetamine 10 mg
Study A02
Treatment Enjoyment Assessment
Questionnaire: Cohort 1
 
 
 
D = 50 mg NRP104, E = 20 mg Dextroamphetamine, F = Placebo
D = 50 mg NRP104
E = 20 mg Dextroamphetamine
F = Placebo
Study A02
PK Data: Cohort 2
Mean NRP104 Concentration-Time Plots
 
 
 
D = 50 mg NRP104
E = 20 mg Dextroamphetamine
F = Placebo
Study A02
PK Data: Cohort 2
Mean d-amphetamine Concentration-Time Plots  Semi‑Logarithmic Scales
 
 
 
 
Mean ± SD
Parameters
NRP104 25 mg
(n = 3)
NRP104 50 mg
(n = 9)
T1/2, h
0.72 ± 0.09
1.25 ± 1.13
AUC0-24, ng·hr/mL
281.9 ± 104.0
598.7 ± 232.9
Cmax, ng/mL
1150 ± 710
1570 ± 779
Tmax, hr
0.09 ± 0.01
0.18 ± 0.20
Study A02
Pharmacokinetic Parameters
for NRP104 
 
 
 
Study A02
Pharmacokinetics Summary
n
Tmax of d-amphetamine after the administration of 25 or 50 mg NRP104 was substantially longer than after 10 or 20 mg d-amphetamine sulfate, respectively
n
Cmax of d-amphetamine after administration of 25 or 50 mg NRP104 was substantially lower (3 to 4 fold) than the Cmax after administration of 10 or 20 mg d-amphetamine sulfate, respectively
n
Within the first 4 hours, exposure to d-amphetamine from NRP104 was substantially lower than from d-amphetamine sulfate
n
T1/2 of intact NRP104 was approximately 1 hour after administration of either 25 or 50 mg of NRP105
–
indicating fast clearance of the intact compound
 
 
 
0.00
5.00
10.00
15.00
20.00
Time, hr
0.00
5.00
10.00
15.00
20.00
Time, hr
0.00
5.00
10.00
15.00
20.00
Time, hr
NRP104 50 mg
Placebo
d-amphetamine 20 mg
Do you feel a drug effect now?
Mean response
Study A02
DRQS – Feel Drug Effect: Cohort 2
 
 
 
NRP104 50 mg
Placebo
d-amphetamine 20 mg
0.00
5.00
10.00
15.00
20.00
Time, hr
0.00
5.00
10.00
15.00
20.00
Time, hr
0.00
5.00
10.00
15.00
20.00
Time, hr
Do you like the drug effect you are feeling now?
Mean Response
Study A02
DRQS – Liking: Cohort 2
 
 
 
Liking
Disliking
A =d-Amphetamine; P = Placebo.
*P < 0.05 compared with placebo.
Study A02
Summary DRQ Measures
Cohort 2 (n = 9)
 
 
 
NC = Not calculable; P = Placebo.
*P < 0.05.
NC
NC
NC
NRP104, mg
d-Amphetamine
Study A02
Correlation Between Mean
d-Amphetamine Plasma Levels and
the Liking Measures
 
 
 
Drug Chosen to Take Again
 
Subject
Drug
1
2
None of the treatments
2
5
d-amphetamine 20 mg
3
6
d-amphetamine 20 mg
4
7
None of the treatments
5
8
NRP104 50 mg
6
9
d-amphetamine 20 mg
7
10
d-amphetamine 20 mg
8
11
d-amphetamine 20 mg
9
12
d-amphetamine 20 mg
Study A02
Treatment Enjoyment
Questionnaire: Cohort 2
 
 
 
Study A02
A02 Conclusions
n
In this IV abuse liability study, NRP104 had less euphoric effects compared to equal doses of d-amphetamine sulfate
n
NRP104 was significantly less reinforcing than d- amphetamine sulfate as evidenced by the majority of the subjects choosing not to take lisdexamfetamine dimesylate again, in the Treatment Enjoyment
Assessment Questionnaire administered at the end of the study
n
This reinforcement profile is consistent with a 2 to 4 fold reduction in peak plasma amphetamine concentration (Cmax) and and increased time to peak
concentration (Tmax) of approximately 2 hours after intravenous administration
 
 
 
Study A03
A Double-Blind, Randomized, Placebo and Active-Controlled, Six-Period Crossover Study to Evaluate the Likeability, Safety, and Abuse Liability of NRP 104 in Healthy Adult Volunteers with Histories of Stimulant Abuse
(NRP104.A03)
 
 
 
Design and Methods
n
30 male and 6 female stimulant abusers
n
Six 6X6 balanced Latin squares for crossover design
n
Primary variable is maximum score on VAS scale to item “ How much do you like the drug effects you are feeling now?”
 
 
 
Drug and doses given orally
n
Placebo
n
40 mg d-amphetamine (Schedule II)
n
200 mg diethylpropion (Schedule IV)
–
Pro-drug
–
Subjective and behavioral effects comparable to
d-amphetamine 40 mg
n
Lisdexamfetamine
50 mg   (base = d-amp 20 mg)
–
–
100 mg  (base = d-amp 40 mg)
–
150 mg  (base = d-amp 60 mg)
 
 
 
Dependent Variable: Do you like the drug effect you are feeling now?
 Drug (I)
 Drug (J)
 Mean  
 Difference
 
 (I - J)
 Std.
 Error
 Significance
 95% Conf. 
 Interval
 
 (Lower
 Bound)
 d-amphetamine 40 mg
 Placebo
4.53* 
1.148 
< 0.001 
1.94 
 diethylpropion 200 mg
 Placebo
4.03* 
1.148 
0.001 
1.44 
 LDX 100 mg
 Placebo
2.14 
1.148 
0.113 
-0.45 
Based on observed means
* - The mean difference is significant at the 0.05 level
Primary Endpoint - Peak
Liking Score
 
 
 
Dependent Variable: Do you like the drug effect you are feeling now?
 Drug (I)
 Drug (J)
 Mean
 Difference
 
 (I - J)
 Std.
 Error
 Significance
 95% Conf.
 Interval 
 
 (Lower
 Bound)
 LDX 50 mg
 Placebo
1.97 
1.148 
0.148 
-0.61 
 LDX 100 mg
 Placebo
2.14 
1.148 
0.113 
-0.45 
 LDX 150 mg
 Placebo
6.06* 
1.148 
0.001 
3.47 
Based on observed means
* - The mean difference is significant at the  0.05 level
Primary Endpoint:
Peak Liking Score
 
 
 
Peak Liking Scores
n
d-amphetamine and diethylpropion
–
1.5 to 2 hours
n
NRP104
–
3 to 4 hours
 
 
 
Top Line Results
n
LDX attenuates onset and intensity of liking effects
n
Liking effects of LDX 50 and 100 mg not significantly different than placebo
n
Liking effects of LDX 150 mg greater thanplacebo but similar to d-amphetamine and diethylpropion; however, mean peak effect
delayed
 
 
 
Top Line Results
n
Rate-limited hydrolysis of LDX in humans
n
Pro-drug attenuates onset and intensity of amphetamine-like effects
n
Attenuated Liking Scale scores
–
Less reinforcing than equivalent d-amphetamine or diethylpropion
–
Contribute to lesser abuse potential

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
Filed on / For Period End:6/26/06
3/15/0610-K
 List all Filings 
↑Top
Filing Submission 0001140361-06-009539   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Tue., Apr. 16, 6:01:33.3pm ET